Le Portail de la recherche de la Société Alzheimer permet de mettre en relation les chercheurs et les Canadiens qui cherchent à participer à des études. Sur ce site, trouvez des études en cours auxquelles vous pouvez participer pour aider à faire avancer la recherche sur les troubles neurocognitifs.
Informal caregivers provide much-needed support to friends, family and loved ones suffering from dementia and related conditions who continue to live at home. Smart home technologies allow providers and caregivers to monitor patients while simultaneously aiding with daily tasks such as remembering to take medications. Although smart home technology has become a common intervention with many benefits, there is very little evidence surrounding informal caregivers’ thoughts, perceptions and needs when patients are utilizing this intervention. There is a necessity to gather insights from this user group to increase uptake and proper use.
Critères d’éligibilité
- Currently a non-medical caregiver of a dementia patient who is living at home
- Over the age of 19
- Able to read, write and speak English
Exclusion Criteria
- Caregiver of a patient who is institutionalized (e.g. living in care facility)
- Under age of 19
- Health Care Professionals (e.g. care aides, hired help)
Alert systems such as United States’ Silver Alert and Scotland’s Purple Alert support first responders in locating missing persons with dementia. In Canada, provinces are responsible for Silver Alerts. To date, Alberta and Manitoba amended Missing Persons Acts, but have no Silver Alerts. British Columbia has a citizen-led Silver Alert, yet no provincial legislation. This study examines how policies and programs for alert systems are developed and implemented in Canada, Scotland, and the United States. Findings will inform policies and implementation of alert systems to optimize the safety and well-being of people living with dementia at risk of going missing.
Critères d’éligibilité
have experience or interest in using Silver Alert to locate missing persons with dementia and are a/an:
Cette étude de phase 2 établira la nécessité d’un traitement efficace pour l’apathie liée aux troubles neurocognitifs et évaluera la sécurité, la tolérabilité et l’efficacité de CVL-871 chez les participant·es présentant ce symptôme.
Critères d’éligibilité
Diagnostic de trouble neurocognitif léger à modéré dû à la maladie d’Alzheimer, à une dégénérescence frontotemporale, à un trouble neurocognitif cérébro-vasculaire ou à la maladie à corps de Lewy.
Suivez-nous :